loading page

Favipiravir Use in Kidney Transplant Recipients with Covid 19: A Single Center Experience
  • +4
  • Burcu Kaya,
  • Dilek Barutcu Atas,
  • Elif Tigen Tükenmez,
  • Ebru Asicioglu,
  • Hakki Arikan ,
  • Serhan Tuglular,
  • Arzu Velioglu
Burcu Kaya
Marmara University School of Medicine
Author Profile
Dilek Barutcu Atas
Marmara University School of Medicine
Author Profile
Elif Tigen Tükenmez
Marmara University School of Medicine
Author Profile
Ebru Asicioglu
Marmara University School of Medicine
Author Profile
Hakki Arikan
Marmara University School of Medicine
Author Profile
Serhan Tuglular
Marmara University School of Medicine
Author Profile
Arzu Velioglu
Marmara University School of Medicine
Author Profile

Abstract

Aim: Kidney transplant patients are amongst the high-risk groups for severe Covid 19. To date, no specific antiviral agent has been found uniformly effective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV2). Favipiravir, the recommended drug by The Turkish Ministry of Health, was uniformly supplied to all patients diagnosed to have COVID 19 with a positive nasopharyngeal swap PCR test. The aim of our study was to retrospectively compare our kidney transplant recipients who developed COVID-19 infection started on Favipiravir to those who did not use Favipiravir for the clinical course of the disease with a special emphasis on the occurrence of side effects/adverse events. Methods: Thirty-seven consecutive KT recipients with a median age of 46 years and of whom 62.2% were women; 8 deceased /29 living related donor, with a 8.0 (5.5-12.5) years median duration of transplantation were included in the study. Results: Twenty-six (70.3%) patients received Favipiravir, 11(29.7%) did not. There was no statistical significance in baseline demographic, clinical and laboratory findings between the groups except that the Favipiravir group was older and had a higher requirement of oxygen treatment. There was no statistically significant difference in the course and outcome of COVID-19 infection, in the occurrence of side effects/adverse events related to Favipiravir between the two groups. Laboratory data at baseline, day7 and 30 were also comparable between the groups. Conclusion: Although the efficacy of Favipiravir in the treatment of COVID-19 infection is currently controversial, Favipiravir can safely be used in kidney transplant patients.

Peer review status:IN REVISION

04 Jun 2021Submitted to International Journal of Clinical Practice
05 Jun 2021Assigned to Editor
05 Jun 2021Submission Checks Completed
07 Jun 2021Reviewer(s) Assigned
08 Jun 2021Review(s) Completed, Editorial Evaluation Pending
08 Jun 2021Editorial Decision: Revise Minor